Check out the latest Genomics Week in Brief – full of intriguing news and research from the genomics space!
Top stories from the past week
- Researchers combined deep learning techniques with genetics and medical data to develop improved diagnostics for schizophrenia and depression. (Allesøe et al)
- In vivo CRISPR screens identified a new immunotherapy target in triple-negative breast cancer. (Ji et al)
- A new study identified a microRNA molecular target for acute myeloid leukaemia treatment. (Liu et al)
- Researchers from the Pamela Sklar Division of Psychiatric Genomics used a racially diverse biobank to conduct a phenome-wide and polygenic risk study into adult weight trajectories. (Xu et al)
- A new study has yielded new genomes after analysing a 100-year-old pandemic flu virus. (Nelson et al)
- A new review discussed the signalling pathways in mitochondria and their potential roles in cancer and neurodegeneration. (Carreras-Sureda et al)
- Canadian researchers reported on the first human identified with complete deficiency of nuclear factor of activated T cells 1. (Sharma et al)
- A new study defined an unconventional protein section that sheds light on Huntington’s disease progression. (Ahat et al)
- New research identified a proteasome-vulnerability that could target non-proliferating persistent cancer cells before drug resistance emerges. (Kim et al)
- Single-cell and spatial transcriptomic techniques have created a roadmap for human gonadal development. (Garcia-Alonso et al)
- Researchers from the University of Washington describe a proof-of-concept time-resolved, multi-symbol molecular recorder via sequential genome editing. (Choi et al)
- A combination of functional imaging and gene-expression profiling in brain tissue has been used to reveal a gene-expression axis that governs each subtype’s activity. (Zeng et al)
In other news:
- Ten years of CRISPR. (Nature)
- Cloned mice created from freeze dried skin cells in world first. (The Guardian)
- Inclusion doesn’t lower standards. (Science Editorial)
- Annual animal research numbers published. (The Francis Crick Institute)
- The first CRISPR gene-editing drug, designed to treat blood disorders, could be on the market by 2023. (Fast Company)
- New colon cancer classification system aims to guide treatment and clinical trials. (Technology Networks)
Image credit: canva
